Filing Flows › Protalix BioTherapeutics (PLX) › Q3 2025
Protalix BioTherapeutics (PLX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
Protalix BioTherapeutics (PLX) reported revenue of $17.9M for the third quarter 2025 (Q3 2025), -0.6% from a year earlier and +14% from the quarter before. Operating margin was 11.9%, net earnings $2.4M (13.2% of revenue).
Protalix BioTherapeutics, Q3 2025: revenue $17.9M (-0.6% year over year), operating margin 11.9%, net earnings $2.4M, operating cash flow −$3.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.9M | +14% | -0.6% |
| Operating profit | $2.1M | +82% | -47% |
| Net earnings | $2.4M | 14× | -27% |
| Operating cash flow | −$3.7M | — | — |
What changed
Revenue was $17.9M in Q3 2025, down 1% year over year and up 14% from the previous quarter. GOODS was the largest line at 99% of revenue. GOODS lost $166K year over year (down 1%), 154% of the total change.
Operating profit was $2.1M, a 11.9% margin (down 10.3 points year over year). Total costs grew 13% against a revenue fall of 1%. The fastest-growing cost line was Research & development (+49%). Net earnings were $2.4M, down 27% year over year. The effective tax rate was -5.2%.
Operating cash flow was −$3.7M. Non-cash charges added back $372K of depreciation and $598K of share-based compensation. Working capital and other items used $7.1M. Capital expenditures of $498K exceeded it, leaving free cash flow of −$4.2M.
Questions
What was Protalix BioTherapeutics' revenue in the third quarter 2025?
Protalix BioTherapeutics (PLX) reported revenue of $17.9M for the third quarter 2025 (Q3 2025), -0.6% from a year earlier and +14% from the quarter before.
Was Protalix BioTherapeutics profitable in the third quarter 2025?
Operating profit was $2.1M (11.9% of revenue) and net earnings $2.4M.